Profusa, Inc. has executed $10.7 million in Series A Convertible Exchange Agreements, converting $4.57 million into Preferred Stock. Investors should note the company's reported net loss of $8.8 million for the second quarter, indicating ongoing challenges.

Key Highlights

  • Profusa executed $10.7 million in Series A Convertible Exchange Agreements, converting $4,570,298 to Preferred Stock.
  • Profusa's cash on hand as of June 30, 2026, was $719,000, with total Assets reported at $1.0 million.
  • Profusa, Inc. has executed agreements to raise $10.7 million through Series A Convertible Exchange Agreements, with $4.57 million converted into Series A Convertible Preferred Stock.

Profusa, Inc. has executed agreements to raise $10.7 million through Series A Convertible Exchange Agreements, with $4.57 million converted into Series A Convertible Preferred Stock. This development comes as the company aims to bolster its Capital Structure following a Reverse Stock Split on August 18, which aims to support compliance with Nasdaq's minimum listing requirements. Stockholders’ equity, previously deficit-driven, is now expected to reach $28.4 million by July 31, 2026.

The successful execution of these agreements is important for Profusa’s strategic positioning as it moves forward in operationalizing its proposed Acquisition of G3 Vision Labs.

Financial Position Highlights Progress

Cash reserves were reported at $719,000 as of June 30, 2026, against total assets of $1.0 million. In contrast, Profusa's liabilities totaled $28.2 million, leading to a stockholders' Deficit of $(27.1) million. The execution of the Option Agreement is significant as it aims to convert some of these obligations into equity, potentially aiding in reducing the overall Debt burden and stabilizing the company's financial standing.

The positive momentum from these actions is intended to foster a solid capital foundation for further developments.

Deepening Loss Amid Financial Maneuvers

For the six-month period, the loss expanded to $(12.2) million from $(5.1) million year-over-year. The mounting losses signal the challenges the company faces as it invests in its planned acquisition and operational restructuring. Executives' ongoing focus will likely shift toward mitigating these operational losses while simultaneously managing the complexities of integration with G3 Vision Labs.

Anticipated Catalysts in Short Term

G3 Vision Labs is finalizing the audits of its 2024 and 2025 financial statements, with complete audits expected by mid-September 2026. The outcome of these audits and their integration into Profusa’s financial framework will be vital for ensuring transparent operations moving forward. Stakeholders should closely monitor these developments as they may provide significant updates regarding financial stability and progress in executing the Option Agreement with G3, impacting future operational strategies.